CHLORPROMAZINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Which patents cover Chlorpromazine Hydrochloride, and what generic alternatives are available?
Chlorpromazine Hydrochloride is a drug marketed by Actavis Mid Atlantic, Genus, Pharm Assoc, Wockhardt, Abraxis Pharm, Dr Reddys, Eugia Pharma, Marsam Pharms Llc, Watson Labs, West-ward Pharms Int, Wyeth Ayerst, Alpharma Us Pharms, Abbott, Amneal Pharms Co, Appco, Cycle, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Kv Pharm, Lannett Co Inc, Lederle, MSN, Purepac Pharm, Pvt Form, Sandoz, Sun Pharm, Teva Pharms, Upsher Smith Labs, Vangard, West Ward, Zameer Pharms, Zydus, and Hikma. and is included in sixty-five NDAs.
The generic ingredient in CHLORPROMAZINE HYDROCHLORIDE is chlorpromazine hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the chlorpromazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chlorpromazine Hydrochloride
A generic version of CHLORPROMAZINE HYDROCHLORIDE was approved as chlorpromazine hydrochloride by ZYDUS on January 17th, 2020.
Summary for CHLORPROMAZINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 33 |
| NDAs: | 65 |
| Finished Product Suppliers / Packagers: | 27 |
| Raw Ingredient (Bulk) Api Vendors: | 120 |
| Clinical Trials: | 36 |
| Patent Applications: | 2,164 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CHLORPROMAZINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CHLORPROMAZINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cancer Prevention Research Institute of Texas | Phase 2/Phase 3 |
| Sadat City University | Phase 1/Phase 2 |
| Varun Monga, MD | Phase 1 |
Pharmacology for CHLORPROMAZINE HYDROCHLORIDE
| Drug Class | Phenothiazine |
Anatomical Therapeutic Chemical (ATC) Classes for CHLORPROMAZINE HYDROCHLORIDE
US Patents and Regulatory Information for CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting CHLORPROMAZINE HYDROCHLORIDE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pvt Form | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 080340-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| West Ward | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 087783-001 | Sep 16, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ivax Sub Teva Pharms | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 083549-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cycle | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 085331-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 215659-004 | Oct 25, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
